Compare 72 telehealth and virtual care platforms independently reviewed by health system CIOs and ambulatory operations leaders. Synchronous video, asynchronous messaging, remote patient monitoring, and hospital-at-home. Verified reviews and pricing transparency. No vendor funding.
The telehealth market has settled into three patterns since the 2020-2022 boom. Health systems standardise on the video module built into their EHR — Epic's MyChart Video and Oracle Health's Virtual Visits — for the bulk of scheduled visits because the workflow integration is unbeatable. Specialty clinics that need richer scheduling, group visits, or branded patient experience choose Doxy.me, Mend, or VSee. Enterprise programs that span virtual urgent care, employer benefits, and direct-to-consumer rely on Amwell or Teladoc.
Remote patient monitoring is a separate procurement. Biofourmis, Current Health, and Cadence dominate hospital-at-home and chronic disease management deployments, billing under CMS RPM and CCM codes. Most platforms now ship clinician-facing AI scribes; buyers should evaluate which scribe the platform integrates with rather than treating it as a feature checkbox.
Procurement criteria typically include EHR launch context, HIPAA and SOC 2 posture, browser-only patient join, group-visit support, and reporting. Compare the two market leaders on our Amwell vs Teladoc page and read the broader virtual care strategy guide. For health-system-wide planning, the healthcare IT hub and healthcare analytics directories are useful adjacent reads.
Index.Html is one of several options in the Telehealth Platforms category on TechVendorIndex. The right way to evaluate it is in the context of your specific buyer profile rather than in isolation: who in your organisation will use it day-to-day, what scale of deployment you need, what existing systems it has to integrate with, and which capabilities are non-negotiable for your use case. Index.Html's strengths land best for buyers who match a particular profile; the related pages and comparisons surface the trade-offs against the most common alternatives so a buyer can decide quickly whether to keep it on the shortlist or rule it out.
Buyers who shortlist Index.Html typically focus their proof-of-concept on three things: depth of functionality in the specific use case that triggered the project, real-world performance and stability under representative load, and the practical experience of integrating with the rest of the existing stack. Vendor-provided demonstration environments rarely surface integration friction, identity-management edge cases, or data-volume scaling limits. A structured pilot against a representative slice of your own data is the single highest-leverage step in the evaluation.
The list price for Index.Html is only one element of the three-year total cost of ownership. Buyers also need to estimate implementation services, internal team time, integration platform fees, training and change-management costs, and any adjacent tooling required to make the product useful in the buyer's specific environment. Vendors often offer attractive year-one pricing that does not reflect the true ongoing cost; ask explicitly for a three-year quote with assumptions documented before signing.
Each profile on TechVendorIndex is reviewed at the same cadence as the parent category. Index.Html's position in the Telehealth Platforms category may shift as competing products release new capabilities, as Index.Html itself releases new versions, or as pricing models change. Buyers who selected Index.Html more than two years ago may want to re-evaluate even if the product is meeting needs today.